S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Why Your IRA Could Crash on January 16th? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Why Your IRA Could Crash on January 16th? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Why Your IRA Could Crash on January 16th? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Why Your IRA Could Crash on January 16th? (Ad)
Estonia to buy US rocket artillery system in $200M deal
Russia rejects $60-a-barrel cap on its oil, warns of cutoffs
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
UK arrests wealthy Russian as police target Putin enablers
Moldova signs new energy deal that could ease blackout risk
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
Tennessee roads plan mulls toll lanes, electric car fee hike
OPEC+ oil producers face uncertainty over Russian sanctions
NASDAQ:CRSP

CRISPR Therapeutics - CRSP Stock Forecast, Price & News

$54.50
+0.16 (+0.29%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$52.63
â–¼
$54.68
50-Day Range
$48.93
â–¼
$66.94
52-Week Range
$42.51
â–¼
$86.95
Volume
742,136 shs
Average Volume
924,869 shs
Market Capitalization
$4.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$101.44

CRISPR Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
86.1% Upside
$101.44 Price Target
Short Interest
Bearish
15.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of CRISPR Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$4.34 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.23) to ($7.97) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.91 out of 5 stars

Medical Sector

743rd out of 1,034 stocks

Biological Products, Except Diagnostic Industry

118th out of 171 stocks

See Top Rated MarketRank™ Stocks Here
CRSP stock logo

About CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Stock News Headlines

December 3, 2022 | americanbankingnews.com
CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Sells $1,350,750.00 in Stock
November 12, 2022 | finance.yahoo.com
We Think CRISPR Therapeutics (NASDAQ:CRSP) Can Afford To Drive Business Growth
December 4, 2022 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
November 10, 2022 | finance.yahoo.com
CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 9, 2022 | finance.yahoo.com
3 Healthcare Stocks That Could Go Parabolic
November 7, 2022 | finance.yahoo.com
Why Shares of CRISPR Therapeutics Dropped 19.9% in October
November 2, 2022 | apnews.com
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
November 2, 2022 | msn.com
Expert Ratings for CRISPR Therapeutics
December 4, 2022 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
November 2, 2022 | markets.businessinsider.com
What 8 Analyst Ratings Have To Say About CRISPR Therapeutics
November 2, 2022 | finance.yahoo.com
CRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag Estimates
October 29, 2022 | finance.yahoo.com
Why Shares of Vertex Pharmaceuticals Jumped 9.03% on Friday
October 27, 2022 | marketwatch.com
CRISPR Therapeutics Chief Operating Officer Lawrence Klein Resigns >CRSP
October 27, 2022 | finance.yahoo.com
Earnings Preview: Exact Sciences (EXAS) Q3 Earnings Expected to Decline
October 26, 2022 | finance.yahoo.com
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?
October 20, 2022 | finance.yahoo.com
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 14, 2022 | seekingalpha.com
CRSP CRISPR Therapeutics AG
October 13, 2022 | msn.com
What 7 Analyst Ratings Have To Say About CRISPR Therapeutics
October 5, 2022 | finance.yahoo.com
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 4, 2022 | finance.yahoo.com
1 Growth Stock That'll Beat Amazon and 1 That Probably Won't (for Now)
September 29, 2022 | finance.yahoo.com
CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy
September 28, 2022 | finance.yahoo.com
Stock Market Gains Strengthen As Yield Backs Away From 4%; This Biotech Soars 35%
September 28, 2022 | finance.yahoo.com
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130â„¢ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
September 27, 2022 | finance.yahoo.com
Why Vertex Pharmaceuticals Stock Triumphed On Tuesday
September 27, 2022 | nasdaq.com
First Week of November 18th Options Trading For CRISPR Therapeutics (CRSP)
September 27, 2022 | nz.finance.yahoo.com
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
September 21, 2022 | seekingalpha.com
Crispr: Elucidating And Forecasting Key Developments
See More Headlines
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Company Calendar

Last Earnings
11/01/2022
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/21/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
CUSIP
N/A
CIK
1674416
Web
www.crisprtx.com
Phone
(141) 561-3277
Fax
N/A
Employees
473
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$101.44
High Stock Price Forecast
$220.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+86.1%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
16 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($8.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$377.66 million
Net Margins
-4,831.79%
Pretax Margin
-4,782.84%
Return on Equity
-31.34%
Return on Assets
-26.77%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.81
Quick Ratio
12.81

Sales & Book Value

Annual Sales
$914.96 million
Price / Sales
4.66
Cash Flow
$5.35 per share
Price / Cash Flow
10.18
Book Value
$24.96 per share
Price / Book
2.18

Miscellaneous

Outstanding Shares
78,290,000
Free Float
74,144,000
Market Cap
$4.27 billion
Optionable
Optionable
Beta
1.70

Key Executives

  • Dr. Rodger Novak M.D. (Age 55)
    Founder, Chairman & Pres
  • Dr. Samarth KulkarniDr. Samarth Kulkarni (Age 43)
    CEO & Director
    Comp: $1.18M
  • Dr. Lawrence Otto Klein Ph.D.Dr. Lawrence Otto Klein Ph.D. (Age 40)
    Chief Operating Officer
    Comp: $675k
  • Mr. James R. KasingerMr. James R. Kasinger (Age 50)
    Gen. Counsel & Sec.
    Comp: $648.93k
  • Mr. Shaun Foy
    Founder
  • Dr. Emmanuelle Marie Charpentier
    Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello Ph.D.
    Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan Ph.D.
    Scientific Founder
  • Dr. Matthew Porteus M.D. (Age 56)
    Ph.D., Scientific Founder & Advisory Board Member
  • Dr. Daniel G. Anderson Ph.D.
    Scientific Founder & Advisory Board Member

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CRSP Stock - Frequently Asked Questions

Should I buy or sell CRISPR Therapeutics stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CRSP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRSP, but not buy additional shares or sell existing shares.
View CRSP analyst ratings or view top-rated stocks.

What is CRISPR Therapeutics' stock price forecast for 2023?

16 brokers have issued twelve-month price objectives for CRISPR Therapeutics' stock. Their CRSP share price forecasts range from $37.00 to $220.00. On average, they predict the company's share price to reach $101.44 in the next year. This suggests a possible upside of 86.1% from the stock's current price.
View analysts price targets for CRSP or view top-rated stocks among Wall Street analysts.

How have CRSP shares performed in 2022?

CRISPR Therapeutics' stock was trading at $75.78 on January 1st, 2022. Since then, CRSP stock has decreased by 28.1% and is now trading at $54.50.
View the best growth stocks for 2022 here.

Are investors shorting CRISPR Therapeutics?

CRISPR Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 11,640,000 shares, a drop of 7.3% from the October 31st total of 12,550,000 shares. Based on an average daily volume of 1,080,000 shares, the short-interest ratio is presently 10.8 days. Approximately 15.5% of the shares of the stock are short sold.
View CRISPR Therapeutics' Short Interest.

When is CRISPR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our CRSP earnings forecast.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) issued its earnings results on Tuesday, November, 1st. The company reported ($2.24) earnings per share for the quarter, topping analysts' consensus estimates of ($2.30) by $0.06. The business had revenue of $0.09 million for the quarter, compared to analysts' expectations of $3.53 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 31.34% and a negative net margin of 4,831.79%.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays acted as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (5.46%), BlackRock Inc. (3.00%), State Street Corp (2.00%), Vanguard Group Inc. (1.83%), Price T Rowe Associates Inc. MD (1.52%) and Bellevue Group AG (1.19%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $54.50.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $4.27 billion and generates $914.96 million in revenue each year. The company earns $377.66 million in net income (profit) each year or ($8.80) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

The company employs 473 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.

This page (NASDAQ:CRSP) was last updated on 12/4/2022 by MarketBeat.com Staff